CAMP
NASDAQCAMP4 Therapeutics Corporation
IPO2024
News · 26 weeks57+500%
2026-03-012026-08-23
Mix3290d
- Insider14(44%)
- SEC Filings8(25%)
- Other6(19%)
- Analyst2(6%)
- Leadership1(3%)
- Offering1(3%)
Latest news
25 items- INSIDERDirector Schwab Andrew J. sold $879,719 worth of shares (191,865 units at $4.59) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERChief Scientific Officer Tardiff Daniel sold $8,273 worth of shares (1,738 units at $4.76), closing all direct ownership in the company (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by CAMP4 Therapeutics CorporationSCHEDULE 13D/A - Camp4 Therapeutics Corp (0001736730) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CAMP4 Therapeutics CorporationSCHEDULE 13G/A - Camp4 Therapeutics Corp (0001736730) (Subject)
- SECSEC Form 10-Q filed by CAMP4 Therapeutics Corporation10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Reports Second Quarter 2026 Financial Results and Corporate HighlightsSecured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year. Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028. WATERTOWN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat
- SECSEC Form EFFECT filed by CAMP4 Therapeutics CorporationEFFECT - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form 424B3 filed by CAMP4 Therapeutics Corporation424B3 - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form S-3 filed by CAMP4 Therapeutics CorporationS-3 - Camp4 Therapeutics Corp (0001736730) (Filer)
- INSIDERSEC Form 4 filed by Large owner 5am Partners Vi, Llc4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Director Schwab Andrew J.4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERDirector Young Richard A bought $27,024 worth of shares (16,378 units at $1.65), increasing direct ownership by 10% to 186,388 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERChief Medical Officer Maricich Yuri bought $10,809 worth of shares (6,551 units at $1.65), increasing direct ownership by 108% to 12,611 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERChief Financial Officer Gold Kelly bought $10,809 worth of shares (6,551 units at $1.65), increasing direct ownership by 10% to 74,428 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERChief Executive Officer Mandel-Brehm Josh bought $10,809 worth of shares (6,551 units at $1.65), increasing direct ownership by 2% to 284,968 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Therapeutics Announces Second Closing of $100 Million Private PlacementCAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the closing of the second tranche of its previously announced private placement pursuant to a securities purchase agreement, dated September 9, 2025, with certain institutional and accredited investors. In connection with the second closing, the Company received approximately $50.1 million in gross proceeds in excha
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderPlanned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025 CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that it has received clearance from Australia’s Therapeutic
- PRCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the "Grant Date"), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Comp
- PRX4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of DirectorsBOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee. "We are thrilled to welcome Kelly to our Board of Directors as she brings a distinct combination of financial leadership, capital markets expertise and a scientific background," said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. "As we continue to strengthen our team to align with
- PRCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the "Grant Date"), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company’s common stock to three newly hired employees of the Company, each as an inducement material to such employee’s entry in
- ANALYSTCAMP4 Therapeutics upgraded by Analyst with a new price targetAnalyst upgraded CAMP4 Therapeutics from Neutral to Overweight and set a new price target of $9.00
- INSIDERSEC Form 4 filed by Director Young Richard A4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
CAMP FAQ
5 questionsWhat does CAMP4 Therapeutics Corporation do?
CalAmp Corp. provides in telematics systems, and software and subscription services in the United States, Europe, the Middle East, Africa, South America, Asia and Pacific Rim, and internationally. The company offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things market, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from...Where does CAMP stock trade?
CAMP4 Therapeutics Corporation (CAMP) is listed on NASDAQ.When did CAMP4 Therapeutics Corporation go public?
CAMP4 Therapeutics Corporation (CAMP) completed its IPO in 2024.What are analysts saying about CAMP?
CAMP4 Therapeutics Corporation has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $900.00 price target on 2026-06-16. Recent price targets range from $650.00 to $1800.00.How can I track CAMP on Quantisnow?
Quantisnow aggregates CAMP4 Therapeutics Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CAMP to receive live email and push alerts on every new disclosure.